Cancer Vaccines Market Unlocking New Revenue Opportunities and Strategic Expansion by 2034 – DelveInsight | Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca

The Key Cancer Vaccines Companies in the market include - Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi, Sanpower Group and CSL Ltd., Northwest Biotherapeutics, IO Biotech, Immunomic Therapeutics, Evaxion Biotech, Candel Therapeutics, Aston Sci, Evaxion Biotech, and others.

 

DelveInsight’s “Cancer Vaccines Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Cancer Vaccines, historical and forecasted epidemiology as well as the Cancer Vaccines market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Cancer Vaccines market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cancer Vaccines Market Forecast

 

Some of the key facts of the Cancer Vaccines Market Report:

• The Cancer Vaccines market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

• In May 2026, Guardant Health announced that the U.S. FDA has approved its Guardant360® CDx liquid biopsy test as a companion diagnostic for VEPPANU (vepdegestrant). Developed collaboratively by Arvinas and Pfizer, VEPPANU is indicated for adults with estrogen receptor-positive (ER+), HER2-negative (HER2-), ESR1-mutated advanced or metastatic breast cancer, identified through an FDA-authorized diagnostic test, whose disease has progressed after receiving at least one prior endocrine therapy.

• In May 2026, The FDA has granted approval to vepdegestrant (Veppanu) for the treatment of patients with estrogen receptor (ER)-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as identified through an FDA-authorized diagnostic test, according to an official agency announcement. In addition, the FDA approved the Guardant360 CDx companion diagnostic to aid in detecting ESR1 mutations in eligible patients. The approval decision was supported by findings from the Phase 3 VERITAC-2 trial (NCT05654623), which evaluated vepdegestrant as a monotherapy for patients with advanced metastatic breast cancer.

• In March 2025, Everest Medicines administered the first dose of EVM16, its personalized mRNA cancer vaccine, to a participant in the first-in-human (FIH) trial, EVM16CX01.

• In February 2025, In a Phase I investigator-led trial, all nine patients who received a personalized kidney cancer vaccine developed anti-cancer immune responses after undergoing tumor removal surgery. Researchers at the Dana-Farber Cancer Institute in the U.S. administered the NeoVax personalized cancer vaccine to patients with stage III or IV clear cell renal cell carcinoma (ccRCC) following their surgeries.

• In 2023, the estimated number of incident cases of non-small cell lung cancer (NSCLC) in the US was approximately 200,000.

• Uveal melanoma impacts approximately 500 to 600 individuals annually in the UK.

• The cancer vaccines market features a robust and expanding pipeline with candidates such as IO102-IO103 (IO Biotech), CAN-2409 (Candel Therapeutics), mRNA-4157 (V940) combined with KEYTRUDA (Merck and Moderna), PDClung01 (PDCline Pharma/LG Chem), and LB-LR1109 (LG Chem and AVEO Oncology). These vaccines target a variety of cancers, including non-small cell lung cancer (NSCLC), colorectal cancer, glioblastoma, melanoma, breast cancer, and more.

• Key Cancer Vaccines Companies: Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi, , Sanpower Group and CSL Ltd., Northwest Biotherapeutics, IO Biotech, Immunomic Therapeutics, Evaxion Biotech, Candel Therapeutics, Aston Sci, Evaxion Biotech, and others

• Key Cancer Vaccines Therapies: DCVax-L, IO102-IO103, ITI-1000, EVX-01, CAN-2409, AST-301, EVX-02, and others

• Several vaccine constructions have been tested for anticancer therapy. In each case, these vaccines are designed to present tumor-associated peptides integrated with MHC molecules to cognate receptors on B or T lymphocytes and stimulate their activation, maturation, and proliferation

• The Cancer Vaccines market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cancer Vaccines pipeline products will significantly revolutionize the Cancer Vaccines market dynamics.

 

Cancer Vaccines Overview

Cancer vaccines are a type of immunotherapy designed to stimulate the body's immune system to recognize and attack cancer cells. Unlike traditional vaccines, which prevent infectious diseases by priming the immune system to recognize and fight off specific pathogens (such as viruses or bacteria), cancer vaccines are used to treat existing cancer or to prevent cancer recurrence.

 

Get a Free sample for the Cancer Vaccines Market Report:

https://www.delveinsight.com/report-store/cancer-vaccines-market

 

Cancer Vaccines Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Cancer Vaccines Epidemiology Segmentation:

The Cancer Vaccines market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Cancer Vaccines

• Prevalent Cases of Cancer Vaccines by severity

• Gender-specific Prevalence of Cancer Vaccines

• Diagnosed Cases of Episodic and Chronic Cancer Vaccines

 

Download the report to understand which factors are driving Cancer Vaccines epidemiology trends @ Cancer Vaccines Epidemiology Forecast

 

Cancer Vaccines Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cancer Vaccines market or expected to get launched during the study period. The analysis covers Cancer Vaccines market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cancer Vaccines Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Cancer Vaccines Therapies and Key Companies

• PROVENGE (sipuleucel-T): Dendreon Pharmaceuticals

• CAN-2409: Candel Therapeutics

• LB-LR1109: LG Chem and AVEO Oncology

• DCVax-L: Northwest Biotherapeutics

• IO102-IO103: IO Biotech

• ITI-1000: Immunomic Therapeutics

• EVX-01: Evaxion Biotech

• CAN-2409: Candel Therapeutics

• AST-301: Aston Sci

• EVX-02: Evaxion Biotech

 

Discover more about therapies set to grab major Cancer Vaccines market share @ Cancer Vaccines Treatment Market

 

Cancer Vaccines Market Drivers

• Rising Global Cancer Burden: The increasing incidence and prevalence of various cancers worldwide are driving demand for innovative preventive and therapeutic cancer vaccines.

• Advancements in Immuno-Oncology: Rapid progress in immunotherapy, including personalized neoantigen vaccines, mRNA vaccine platforms, and dendritic cell-based therapies, is expanding the cancer vaccines market.

• Growing Investment in R&D: Pharmaceutical and biotechnology companies are significantly increasing investments in cancer vaccine research, supported by strategic collaborations, licensing agreements, and public funding.

• Success of mRNA Technology: The clinical success of mRNA platforms has accelerated the development of personalized cancer vaccines, enabling faster vaccine design and manufacturing.

• Favorable Regulatory Incentives: Regulatory designations such as Orphan Drug, Fast Track, Breakthrough Therapy, and Priority Review are encouraging the development and commercialization of novel cancer vaccines.

 

Cancer Vaccines Market Barriers

• Complex Tumor Biology: Tumor heterogeneity, immune evasion mechanisms, and variations in patient immune responses make the development of effective cancer vaccines highly challenging.

• High Development Costs: Cancer vaccine research involves substantial investments in biomarker identification, clinical trials, manufacturing, and regulatory compliance, increasing overall development expenses.

• Lengthy Clinical Development Timelines: Demonstrating long-term efficacy, survival benefits, and immune response often requires extended clinical trials, delaying product commercialization.

• Manufacturing and Scalability Challenges: Personalized cancer vaccines require complex, patient-specific manufacturing processes, limiting scalability and increasing production costs.

• Limited Clinical Success Rates: Despite a growing pipeline, many investigational cancer vaccines fail to demonstrate significant efficacy in late-stage clinical trials.

 

Scope of the Cancer Vaccines Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Cancer Vaccines Companies: Dendreon Pharma, Candel Therapeutics, GlaxoSmithKline, Merck, Aduro Biotech, Astrazeneca Plc, Dendreon, Astellas Pharma Inc, Sanofi, Sanpower Group and CSL Ltd., Northwest Biotherapeutics, IO Biotech, Immunomic Therapeutics, Evaxion Biotech, Candel Therapeutics, Aston Sci, Evaxion Biotech, and others

• Key Cancer Vaccines Therapies: DCVax-L, IO102-IO103, ITI-1000, EVX-01, CAN-2409, AST-301, EVX-02, and others

• Cancer Vaccines Therapeutic Assessment: Cancer Vaccines current marketed and Cancer Vaccines emerging therapies

• Cancer Vaccines Market Dynamics: Cancer Vaccines market drivers and Cancer Vaccines market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Cancer Vaccines Unmet Needs, KOL’s views, Analyst’s views, Cancer Vaccines Market Access and Reimbursement

 

To know more about Cancer Vaccines companies working in the treatment market, visit @ Cancer Vaccines Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Cancer Vaccines Market Report Introduction

2. Executive Summary for Cancer Vaccines

3. SWOT analysis of Cancer Vaccines

4. Cancer Vaccines Patient Share (%) Overview at a Glance

5. Cancer Vaccines Market Overview at a Glance

6. Cancer Vaccines Disease Background and Overview

7. Cancer Vaccines Epidemiology and Patient Population

8. Country-Specific Patient Population of Cancer Vaccines

9. Cancer Vaccines Current Treatment and Medical Practices

10. Cancer Vaccines Unmet Needs

11. Cancer Vaccines Emerging Therapies

12. Cancer Vaccines Market Outlook

13. Country-Wise Cancer Vaccines Market Analysis (2020–2034)

14. Cancer Vaccines Market Access and Reimbursement of Therapies

15. Cancer Vaccines Market Drivers

16. Cancer Vaccines Market Barriers

17. Cancer Vaccines Appendix

18. Cancer Vaccines Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Proposed Etiwanda Heights Development Raises Infrastructure Questions in Rancho Cucamonga

This graphic courtesy of the Rancho Cucamonga Preservation Society illustrates the number of homes in neighborhoods surrounding Etiwanda Heights

Rancho Cucamonga City Council candidate David VanGorden says visual comparison highlights the importance of planning roads, public safety, utilities, and community services before large-scale growth.

RANCHO CUCAMONGA, Calif. - As Rancho Cucamonga continues to grow, residents are increasingly asking whether infrastructure planning is keeping pace with proposed residential development.

A visual comparison recently circulating online illustrates the scale of the proposed Etiwanda Heights community by comparing its planned approximately 6,300 homes with nearby established neighborhoods, many of which contain only a few hundred homes.

While the comparison focuses on housing numbers rather than development design, it raises broader questions about how infrastructure will accommodate future growth.

Rancho Cucamonga City Council candidate David VanGorden believes the discussion should extend beyond the number of homes to the city's long-term ability to support additional residents.

"Whenever a development of this size is proposed, residents naturally begin asking how it will affect traffic, emergency services, water resources, schools, parks, and other public infrastructure," VanGorden said. "Those are reasonable questions that deserve clear, transparent answers."

VanGorden said responsible planning requires evaluating the cumulative impact of large developments before construction begins.

"As our city grows, infrastructure should grow alongside it," he said. "Growth and quality of life should go hand in hand."

Residents throughout Rancho Cucamonga have repeatedly expressed concerns about increasing traffic congestion on major corridors and whether existing public services can keep pace with continued residential expansion.

VanGorden says discussions surrounding future development should include detailed information about roadway capacity, emergency response resources, utility infrastructure, and long-term planning so residents can better understand how projects will affect the community over time.

"Development decisions shape Rancho Cucamonga for decades," VanGorden said. "Residents deserve confidence that infrastructure planning has been carefully considered before projects of this magnitude move forward."

VanGorden encourages continued public engagement and believes open communication between residents and city leadership is essential as Rancho Cucamonga plans for its future.

David VanGorden is a candidate for Rancho Cucamonga City Council, District 2. He is running against incumbent Kristine Scott and candidate DeJonae Shaw in the November 3, 2026 election. His campaign emphasizes transparent government, responsible growth, public safety, fiscal responsibility, and maintaining an open dialogue with residents throughout the city.

For more information, visit www.VanGordenForRancho.com.

Media Contact
Company Name: Keith Hunt Marketing
Contact Person: Keith Hunt
Email:Send Email
Phone: 9096364012
Country: United States
Website: http://www.KeithHuntMarketing.com/

Benign Prostatic Hyperplasia Market Forecast Signals Robust Industry Growth Through 2034 – DelveInsight | AiViva BioPharma, Chong Kun Dang, EMS, Urotronic, Resurge Therapeutics, Antev, Nymox Pharma

The Key Benign Prostatic Hyperplasia Companies in the market include - AiViva BioPharma, Chong Kun Dang, EMS, Urotronic Inc., Resurge Therapeutics Inc, Antev, Nymox Pharmaceutical, GlaxoSmithKline, Dongkook Pharmaceutical, RECORDATI GROUP, Astellas Pharma Inc, Eli Lilly and Company, Sophiris Bio Corp, Bayer, Sophiris Bio Corp, Warner Chilcott, Nymox Corporation, QLT Inc., NeoTract, Inc., Xintian Pharmaceutical, and others.

DelveInsight’s “Benign Prostatic Hyperplasia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Benign Prostatic Hyperplasia, historical and forecasted epidemiology as well as the Benign Prostatic Hyperplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Benign Prostatic Hyperplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Benign Prostatic Hyperplasia Market Forecast

 

Some of the key facts of the Benign Prostatic Hyperplasia Market Report:

• The Benign Prostatic Hyperplasia market size is anticipated to grow with a significant CAGR during the study period (2020-2034).

• In June 2026, The FDA has granted approval for a feasibility study of the NanoKnife System, which will evaluate irreversible electroporation (IRE) as a potential treatment for lower urinary tract symptoms (LUTS) resulting from benign prostatic hyperplasia (BPH).

• In March 2026, Prodeon Medical has obtained U.S. Food and Drug Administration (FDA) 510(k) clearance for its Urocross Expander System, a temporary implant technology designed to treat lower urinary tract symptoms (LUTS) linked to benign prostatic hyperplasia (BPH).

• In January 2026, Butterfly Medical, a company developing a proprietary non-surgical treatment for benign prostatic hyperplasia (BPH), has announced the successful completion of the final 12-month follow-up for all participants in its international pivotal clinical trial. This landmark study aims to assess the safety and effectiveness of the Butterfly Prostatic Retraction Device, a first-line interventional therapy (FIT) for BPH.

• In December 2025, Zenflow, Inc. announced that the FDA has approved its Zenflow Spring Implant and Delivery System for the treatment of symptoms related to benign prostatic hyperplasia (BPH). This first-line interventional therapy is designed to widen the urethra while maintaining natural anatomy through a proprietary spring-like implant. The company also highlighted that this is the first FDA-approved BPH treatment performed in an outpatient setting using the Zenflow Spring Scope, which received FDA 510(k) clearance earlier this year.

• In August 2025, Jyong Biotech Ltd. (Nasdaq: MENS), a Taiwan-based, science-driven biotechnology company focused on developing and commercializing innovative plant-derived drugs for urinary system disorders, with initial market focus on the U.S., EU, and Asia, announced its participation in the 22nd Urological Association of Asia Congress held alongside the 47th Annual Meeting of the Taiwan Urological Association from August 14–17, 2025. The company presented topline results from multiple clinical studies of its proprietary drug candidates: BOTRESO® for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), and MCS‑8 (PCP) for potential prostate cancer prevention.

• In April 2025, The investigational ProVee Urethral Expander System for benign prostatic hyperplasia (BPH) met all safety and effectiveness endpoints in a Phase 3 study, as reported at the 2025 American Urological Association Annual Meeting. Steven A. Kaplan, MD, presented data from the ProVIDE trial (NCT05186740), a Phase 3, prospective, multicenter, randomized, double-blind, sham-controlled study assessing the safety, performance, and effectiveness of ProVee. Patients were randomly assigned in a 2:1 ratio to receive either ProVee or a sham procedure (simulated delivery with no stent deployed). The study included men aged 45 and older with moderate-to-severe symptomatic BPH, an International Prostate Symptom Score (IPSS) of at least 13, and an IPSS V/S of at least 1 at baseline.

• In April 2025, The investigational ProVee Urethral Expander System for benign prostatic hyperplasia (BPH) met all safety and effectiveness endpoints in a Phase 3 study, as reported at the 2025 American Urological Association Annual Meeting. Steven A. Kaplan, MD, presented data from the ProVIDE trial (NCT05186740), a Phase 3, prospective, multicenter, randomized, double-blind, sham-controlled study assessing the safety, performance, and effectiveness of ProVee. Patients were randomly assigned in a 2:1 ratio to receive either ProVee or a sham procedure (simulated delivery with no stent deployed). The study included men aged 45 and older with moderate-to-severe symptomatic BPH, an International Prostate Symptom Score (IPSS) of at least 13, and an IPSS V/S of at least 1 at baseline.

• The alpha blockers approved by the US FDA include terazosin (HYTRIN), doxazosin (CARDURA), tamsulosin (FLOMAX), alfuzosin (UROXATRAL), and silodosin (RAPAFLO).

• The key driver of the BPH market's growth is the increasing prevalence of risk factors such as obesity, cardiovascular diseases, type 2 diabetes, and the rising aging population.

• Benign prostatic hyperplasia is the most prevalent prostate condition among men over 50.

• Among the seven major markets (7MM), the United States had the highest total prevalence of BPH.

• According to DelveInsight's analysis, nearly 80% of men over the age of 80 experience lower urinary tract symptoms due to benign prostatic hyperplasia.

• Key Benign Prostatic Hyperplasia Companies: AiViva BioPharma, Chong Kun Dang, EMS, Urotronic Inc., Resurge Therapeutics Inc, Antev, Nymox Pharmaceutical, GlaxoSmithKline, Dongkook Pharmaceutical, RECORDATI GROUP, Astellas Pharma Inc, Eli Lilly and Company, Sophiris Bio Corp, Bayer, Sophiris Bio Corp, Warner Chilcott, Nymox Corporation, QLT Inc., NeoTract, Inc., Xintian Pharmaceutical, and others

• Key Benign Prostatic Hyperplasia Therapies: AIV007, CKD-846, DTT106, Paclitaxel, RT-310, Teverelix trifluoroacetate, Fexapotide, GI198745, DKF-313, Silodosin, ASP4901, Tadalafil, PRX302, Levitra (Vardenafil, BAY38-9456), PRX302, WC3055, NX-1207, QLT0074, Tamsulosin Hydrochloride, Ningmitai capsule, and others

• The Benign Prostatic Hyperplasia epidemiology based on age-specific cases analyzed that Benign Prostatic Hyperplasia is more common in older males as compared to those below 40 years

• The Benign Prostatic Hyperplasia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Benign Prostatic Hyperplasia pipeline products will significantly revolutionize the Benign Prostatic Hyperplasia market dynamics.

 

Benign Prostatic Hyperplasia Overview

Benign prostatic hyperplasia (BPH), also known as prostate gland enlargement, is a common condition that affects aging men. It occurs when the prostate gland, which surrounds the urethra (the tube that carries urine from the bladder out of the body), gradually enlarges. The prostate gland's enlargement can cause compression of the urethra, leading to various urinary symptoms.

 

Get a Free sample for the Benign Prostatic Hyperplasia Market Report:

https://www.delveinsight.com/report-store/benign-prostatic-hyperplasia-bph-market

 

Benign Prostatic Hyperplasia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Benign Prostatic Hyperplasia Epidemiology Segmentation:

The Benign Prostatic Hyperplasia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Benign Prostatic Hyperplasia

• Prevalent Cases of Benign Prostatic Hyperplasia by severity

• Gender-specific Prevalence of Benign Prostatic Hyperplasia

• Diagnosed Cases of Episodic and Chronic Benign Prostatic Hyperplasia

 

Download the report to understand which factors are driving Benign Prostatic Hyperplasia epidemiology trends @ Benign Prostatic Hyperplasia Epidemiology Forecast

 

Benign Prostatic Hyperplasia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Benign Prostatic Hyperplasia market or expected to get launched during the study period. The analysis covers Benign Prostatic Hyperplasia market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Benign Prostatic Hyperplasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Benign Prostatic Hyperplasia Therapies and Key Companies

• AIV007: AiViva BioPharma

• CKD-846: Chong Kun Dang

• DTT106: EMS

• Paclitaxel: Urotronic Inc.

• RT-310: Resurge Therapeutics Inc

• Teverelix trifluoroacetate Antev

• Fexapotide: Nymox Pharmaceutical

• GI198745: GlaxoSmithKline

• DKF-313: Dongkook Pharmaceutical

• Silodosin: RECORDATI GROUP

• ASP4901: Astellas Pharma Inc

• Tadalafil: Eli Lilly and Company

• PRX302: Sophiris Bio Corp

• Levitra (Vardenafil, BAY38-9456): Bayer

• PRX302: Sophiris Bio Corp

• WC3055: Warner Chilcott

• NX-1207: Nymox Corporation

• QLT0074: QLT Inc.

• Tamsulosin Hydrochloride: NeoTract, Inc.

• Ningmitai capsule: Xintian Pharmaceutical

 

Discover more about therapies set to grab major Benign Prostatic Hyperplasia market share @ Benign Prostatic Hyperplasia Treatment Market

 

Benign Prostatic Hyperplasia Market Drivers

• Rising prevalence of benign prostatic hyperplasia due to the growing aging male population.

• Increasing awareness and early diagnosis of lower urinary tract symptoms (LUTS).

• Growing demand for minimally invasive and office-based treatment options.

• Continuous advancements in medical devices, laser therapies, and robotic technologies.

• Expanding adoption of novel pharmaceuticals with improved efficacy and safety profiles.

• Favorable reimbursement policies for BPH diagnosis and treatment in developed markets.

 

Benign Prostatic Hyperplasia Market Barriers

• High cost of advanced minimally invasive procedures and surgical devices.

• Availability of low-cost generic medications, limiting the uptake of newer therapies.

• Risk of treatment-related complications, including urinary incontinence.

• Preference for conservative management in patients with mild or moderate symptoms.

• Limited awareness and access to advanced treatment options in emerging economies.

• Stringent regulatory requirements for approval of novel drugs and medical devices.

• Variability in reimbursement coverage across different countries and healthcare systems.

Scope of the Benign Prostatic Hyperplasia Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Benign Prostatic Hyperplasia Companies: AiViva BioPharma, Chong Kun Dang, EMS, Urotronic Inc., Resurge Therapeutics Inc, Antev, Nymox Pharmaceutical, GlaxoSmithKline, Dongkook Pharmaceutical, RECORDATI GROUP, Astellas Pharma Inc, Eli Lilly and Company, Sophiris Bio Corp, Bayer, Sophiris Bio Corp, Warner Chilcott, Nymox Corporation, QLT Inc., NeoTract, Inc., Xintian Pharmaceutical, and others

• Key Benign Prostatic Hyperplasia Therapies: AIV007, CKD-846, DTT106, Paclitaxel, RT-310, Teverelix trifluoroacetate, Fexapotide, GI198745, DKF-313, Silodosin, ASP4901, Tadalafil, PRX302, Levitra (Vardenafil, BAY38-9456), PRX302, WC3055, NX-1207, QLT0074, Tamsulosin Hydrochloride, Ningmitai capsule, and others

• Benign Prostatic Hyperplasia Therapeutic Assessment: Benign Prostatic Hyperplasia current marketed and Benign Prostatic Hyperplasia emerging therapies

• Benign Prostatic Hyperplasia Market Dynamics: Benign Prostatic Hyperplasia market drivers and Benign Prostatic Hyperplasia market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Benign Prostatic Hyperplasia Unmet Needs, KOL’s views, Analyst’s views, Benign Prostatic Hyperplasia Market Access and Reimbursement

 

To know more about Benign Prostatic Hyperplasia companies working in the treatment market, visit @ Benign Prostatic Hyperplasia Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Benign Prostatic Hyperplasia Market Report Introduction

2. Executive Summary for Benign Prostatic Hyperplasia

3. SWOT analysis of Benign Prostatic Hyperplasia

4. Benign Prostatic Hyperplasia Patient Share (%) Overview at a Glance

5. Benign Prostatic Hyperplasia Market Overview at a Glance

6. Benign Prostatic Hyperplasia Disease Background and Overview

7. Benign Prostatic Hyperplasia Epidemiology and Patient Population

8. Country-Specific Patient Population of Benign Prostatic Hyperplasia

9. Benign Prostatic Hyperplasia Current Treatment and Medical Practices

10. Benign Prostatic Hyperplasia Unmet Needs

11. Benign Prostatic Hyperplasia Emerging Therapies

12. Benign Prostatic Hyperplasia Market Outlook

13. Country-Wise Benign Prostatic Hyperplasia Market Analysis (2020–2034)

14. Benign Prostatic Hyperplasia Market Access and Reimbursement of Therapies

15. Benign Prostatic Hyperplasia Market Drivers

16. Benign Prostatic Hyperplasia Market Barriers

17. Benign Prostatic Hyperplasia Appendix

18. Benign Prostatic Hyperplasia Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

AIS and Motorola Solutions to Host AI Campus Safety Summit

“Campus safety requires more than cameras and alarms. It requires connected intelligence, faster investigations, and stronger collaboration between schools, technology partners, and public safety teams,” said Danny Haddad, VP of Sales & Customer Experience at AIS. “The AI Campus Safety Summit is designed to give education leaders a practical look at how today’s security technologies can help protect students, staff, and communities more effectively.”

AIS, Motorola Solutions, Avigilon, and Alpha Vision are hosting the AI Campus Safety Summit 2026, a free event for K-12 and higher education leaders. The summit will feature expert-led sessions on AI-powered video analytics, emergency communications, and regional safety collaboration to help campuses improve security response and modern infrastructure.

Dublin, CA - July 1, 2026 - Alpha Integrated Solutions, in collaboration with Motorola Solutions, Avigilon, Alpha Vision, today announced the upcoming AI Campus Safety Summit 2026, an exclusive lunch-and-learn event focused on the future of campus safety, security technology, and regional collaboration.

Designed for K-12 and higher education leaders, the AI Campus Safety Summit will bring together education, technology, and public safety stakeholders to discuss emerging security solutions and best practices for safer learning environments. Attendees will learn how modern video security, AI-powered investigations, access control, emergency communications, real-time intelligence, and connected community safety networks can help campuses respond faster, collaborate more effectively, and strengthen overall security readiness.

“Campus safety requires more than cameras and alarms. It requires connected intelligence, faster investigations, and stronger collaboration between schools, technology partners, and public safety teams,” said Danny Haddad, VP of Sales & Customer Experience at AIS. “The AI Campus Safety Summit is designed to give education leaders a practical look at how today’s security technologies can help protect students, staff, and communities more effectively.”

The summit will feature sessions from Motorola Solutions and Avigilon, Alpha Vision, covering a wide range of campus safety modernization strategies. Topics will include video management, cloud security, access control, sensors, intercoms, body-worn cameras, license plate recognition, emergency communications, AI-powered investigations, natural language video search, real-time alerts, camera modernization, RTCC tools, secure video sharing, connected intelligence, grants, and regional safety best practices.

For school districts, higher education institutions, and public safety partners, the event will provide a practical opportunity to explore how modern security infrastructure can support faster incident review, stronger emergency response, improved situational awareness, and more effective collaboration with law enforcement.

“Campus safety modernization is not just about adding more technology. It is about helping education leaders act faster, collaborate better, and make more informed decisions during critical moments,” said Yi Jin, Ph.D.,Co-Founder and Chief Marketing Officer at Alpha Vision.“This summit is an opportunity to show how AI-powered video intelligence and connected response workflows can support safer learning environments.”

The AI Campus Safety Summit comes at a time when education leaders are facing growing pressure to modernize campus security while improving emergency preparedness, operational visibility, and coordination with public safety agencies. By bringing together leading technology providers and regional safety partners, the summit aims to help attendees better understand what is possible today and how to plan for the next generation of connected campus safety.

AIS delivers comprehensive security architectures, ranging from off-grid solar-powered surveillance to advanced AI video intelligence like Magic Search and Smart Link, ensuring complete protection for diverse physical environments.

Event Highlights

• Modern Video Security: Learn how video management, cloud security, and camera modernization can improve campus visibility and response.

• AI-Powered Investigations: Explore how natural language video search and intelligent video analytics can help teams find relevant footage faster.

• Access Control and Emergency Communications: Understand how access control, sensors, intercoms, and emergency communication systems can support safer campus operations.

• Real-Time Intelligence: Discover how real-time alerts, RTCC tools, and connected safety platforms can improve situational awareness.

• School and Law Enforcement Collaboration: Learn best practices for secure video sharing, regional safety coordination, and connected community safety networks.

• Funding and Deployment Guidance: Explore grants, deployment options, and practical strategies for campus safety modernization.

About AIS (Alpha Integrated Solutions):

Based in Livermore, CA, AIS (Alpha Integrated Solutions) designs, installs, and manages intelligent, end-to-end security ecosystems for California organizations. Capabilities include AI-powered video surveillance, cloud-based access control, virtual guarding, and autonomous robotics. By combining enterprise-grade technology with proactive active-deterrence strategies, such as remote talk-down intervention and real-time behavioral analytics, AIS ensures facilities remain protected, compliant, and monitored around the clock.

About Motorola Solutions:

Motorola Solutions is a global leader in public safety and enterprise security. We build a cohesive ecosystem of mission-critical communications, command center software, and video security technology. By integrating advanced analytics with proven reliability, we empower schools and public safety agencies to act faster, collaborate more effectively, and protect communities with comprehensive, end-to-end security solutions.

About Avigilon:

Avigilon, a Motorola Solutions company, provides advanced AI-powered video surveillance and analytics solutions designed for enterprise and educational environments. Known for high-definition imaging and self-learning analytics, Avigilon helps organizations proactively detect threats, streamline investigations through intelligent forensic search, and strengthen situational awareness. Our technology enables schools to secure perimeters, manage access, and respond to critical incidents with unmatched clarity and accuracy.

About Alpha Vision:

Located in the heart of Silicon Valley in Campbell, CA, Alpha Vision delivers an Agentic Video Intelligence Platform that transforms passive surveillance into actionable insight. By integrating natural language search capabilities, automated case building, and intelligent forensic investigation tools, Alpha Vision helps security teams and educational institutions streamline incident review and improve response times. Our platform empowers users to turn massive amounts of visual data into clear, evidence-based reports, ensuring safer learning environments through data-driven decision-making.

Media Contact
Company Name: AIS (Alpha Integrated Solutions)
Contact Person: Yi Jin, Ph.D.
Email:Send Email
Phone: (925) 512-5742
Address:4374 Contractors Place Suite A/B
City: Livermore
State: CA
Country: United States
Website: https://alphaintegratedsolutions.ai/

Alpha Vision Announces Safer Community Network to Help Businesses Strengthen Community Safety

“Public safety works best when businesses, communities, and law enforcement can act together with speed and accuracy,” said Song Cao, Founder and CEO of Alpha Vision. “The Safer Community Network helps transform existing camera infrastructure into real-time intelligence, giving responders better context and giving communities a stronger way to prevent crime and respond faster.”

Alpha Vision’s new Safer Community Network empowers businesses, law enforcement, and first responders to enhance public safety. By integrating existing camera systems with real-time AI analytics, the program provides instant crime alerts, license plate recognition, and rapid incident insights. This initiative fosters stronger community collaboration, enabling faster, more informed responses to protect storefronts, commercial properties, and the public.

Campbell, CA - July 1st, 2026 - Alpha Vision, a Silicon Valley–based video security intelligence platform for physical security, today announced the Safer Community Network, a real-time AI analytics program designed to help businesses, first responders, and law enforcement work together to create safer communities.

The Safer Community Network helps participating businesses connect their existing cameras to an AI-powered solution that supports instant crime alerts, license plate recognition, 24/7 real-time monitoring, faster response, and community camera integration. The program is designed to equip first responders and law enforcement with critical information before a situation escalates.

“Public safety works best when businesses, communities, and law enforcement can act together with speed and accuracy,” said Song Cao, Founder and CEO of Alpha Vision. “The Safer Community Network helps transform existing camera infrastructure into real-time intelligence, giving responders better context and giving communities a stronger way to prevent crime and respond faster.”

Through the program, Alpha Vision helps businesses keep eyes on their perimeter, even after hours, while enabling automatic notifications to be sent directly to dispatchers. The platform can also support license plate recognition to help law enforcement identify stolen vehicles, suspects, missing persons, and other vehicles of interest in seconds.

The Safer Community Network is built to enhance existing systems, not replace them. Participating organizations can connect fixed, mobile, cloud, or temporary cameras into one unified view. The program can also support mobile surveillance, emergency dispatch support, remote monitoring, virtual guarding, and community-wide intelligence powered by AI search across objects and activity.

“Many businesses already have cameras, but those cameras often operate in isolation,” said Song. “By connecting those systems into a coordinated safety network, Alpha Vision helps improve awareness, speed up investigations, and give public safety partners better information when it matters most.”

The program is especially relevant for commercial and retail businesses with storefront locations. Through the STAART Small Business Camera Grant Program, eligible businesses may qualify for free cameras, free installation, and free software, helping expand participation in the Safer Community Network while reducing barriers to adoption.

“This program reflects a broader shift in how communities can use AI to improve safety, response, and collaboration,” said Yi Jin, Ph.D., Co-Founder and Chief Marketing Officer at Alpha Vision. “By helping businesses connect existing cameras, automate alerts, and share critical information more efficiently, the Safer Community Network makes advanced video intelligence more accessible to local communities. Our goal is to help public safety teams and business owners act faster, understand incidents better, and protect people and property with greater confidence.”

Alpha Vision’s community-first approach is designed to serve neighborhoods and public spaces by prioritizing local collaboration. The program is flexible, scalable, and easy to deploy across small properties, large networks, and multi-location environments. By combining AI-powered analytics, real-time alerts, and secure law enforcement sharing, Alpha Vision helps communities strengthen protection without adding unnecessary complexity.

Key Solution Highlights

• Instant Crime Alerts: Send automatic notifications straight to dispatchers to support faster awareness and response.

• License Plate Recognition: Help law enforcement identify stolen vehicles, suspects, missing persons, and vehicles of interest in seconds.

• 24/7 Real-Time Monitoring: Keep eyes on business perimeters, storefronts, and surrounding areas even after hours.

• Crime Prevention and Faster Response: Equip first responders with critical information before a situation escalates.

• Community Camera Integration: Connect existing cameras to participating law enforcement agencies at an affordable cost.

• Video and Camera Networks: Connect fixed, mobile, cloud, or temporary cameras into one unified view.

• Emergency Dispatch Support: Provide faster access to visual information during active incidents.

• Remote Monitoring and Virtual Guarding: Use live operators to help identify threats and coordinate response when needed.

• Community-Wide Intelligence: Use AI-powered search across objects and activity to improve awareness and response time.

About Alpha Vision:

Alpha Vision is an agentic video intelligence platform that transforms traditional surveillance into AI-powered security and operational intelligence. By combining advanced video understanding, natural language search, automated reporting, and workflow automation, the platform enables teams to act faster across all environments.

Media Contact
Company Name: Alpha Vision
Contact Person: Yi Jin
Email:Send Email
Address:1901 S. Bascom Avenue #1180
City: Campbell
State: CA
Country: United States
Website: https://alphavision.ai/safer-community-network

HX Appoints James Munce to Its Board of Directors to Accelerate Global Growth, Capital Strategy and GCC Expansion

Abu Dhabi, UAE & Detroit, USA & London, UK - 1st July, 2026 - HX, the global intelligence and market activation platform focused on hydrogen and clean molecules, today announced the appointment of James Munce to its Board of Directors.

James joins HX at a pivotal point in the company’s global expansion as it advances its market intelligence, infrastructure activation and ecosystem development activities across hydrogen, ammonia, methanol, sustainable aviation fuel (SAF) and wider clean energy markets.

A highly accomplished financial executive with more than 25 years of experience in investment management, corporate finance and institutional capital, James brings extensive expertise spanning global fund leadership, governance, capital formation and strategic market development.

A qualified Chartered Accountant trained at PwC and an Economics graduate, James began his career in finance before progressing to senior leadership positions including at Merrill Lynch in London, where he ultimately became Chief Executive Officer of the Merrill Lynch Investment Solutions Fund Platform.

In 2018, James relocated to Abu Dhabi to serve as Chief Executive Officer and Chief Investment Officer of Abu Dhabi Catalyst Partners, a US$1 billion Mubadala-backed investment platform established to support the growth of the Abu Dhabi financial ecosystem and the Abu Dhabi Global Market.

More recently, James served as Founding Chief Executive Officer and Chief Investment Officer of HYCAP, leading the establishment of a dedicated energy transition investment platform focused on accelerating deployment and investment across the clean energy sector.

Throughout his career, James has built deep expertise in institutional investment, capital raising, governance, stakeholder engagement and international market development, with significant experience across the Middle East, Europe and global financial markets.

Clayton Kingman, CEO of HX, commented: "James brings an exceptional combination of institutional finance, global capital markets experience and strategic leadership at exactly the right time for HX. As we continue building hydrogen ecosystems, enabling market activation and supporting large-scale deployment globally, James’ experience in investment strategy, governance and scaling institutional platforms will be hugely valuable to our next phase of growth."

Commenting on his appointment, James Munce said: "HX is addressing one of the most important challenges facing the energy transition - creating the intelligence, coordination and market structures required to accelerate deployment at scale. I am excited to join the Board and support HX as it continues to build practical pathways for market development, investment and ecosystem growth globally."

James will support HX’s strategic growth agenda, with a particular focus on institutional capital strategy, international partnerships and expansion opportunities across key global markets, including the GCC.

HX is building a global intelligence and market activation platform designed to support the growth of hydrogen and associated clean molecule economies through market intelligence, cost and carbon analysis, ecosystem development, infrastructure coordination and deployment enablement.

Media Enquiries HX Info@hxgroup.io hxgroup.io

About HX

HX is a global intelligence, market activation and ecosystem development platform focused on hydrogen and related clean molecules including ammonia, methanol, sustainable aviation fuel (SAF) and biofuels. HX works with governments, industry and investors to accelerate deployment, improve market visibility and support the development of investable clean energy ecosystems.

For more info: www.hxgroup.io

#HXGroup #HydrogenMarketIntelligence #CleanMoleculeEconomy #HydrogenInvestment #HXBoardOfDirectors #GCCHydrogenExpansion

Media Contact
Company Name: HX
Contact Person: Aaron Bazin
Email:Send Email
Country: United States
Website: https://www.hydrogenexchange.io/

AL Amyloidosis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharma, Takeda

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, AL Amyloidosis pipeline constitutes 10+ key companies continuously working towards developing 10+ AL Amyloidosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

 

“AL Amyloidosis Pipeline Insight, 2026" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the AL Amyloidosis Market.

 

The AL Amyloidosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the AL Amyloidosis Pipeline Report:

• Companies across the globe are diligently working toward developing novel AL Amyloidosis treatment therapies with a considerable amount of success over the years.

• AL Amyloidosis companies working in the treatment market are HaemaLogiX, Zentalis Pharmaceuticals, Sorrento Therapeutics, Sanofi, Astellas Pharma GmbH, GlaxoSmithKline, Takeda Oncology, Caelum Biosciences, and others, are developing therapies for the AL Amyloidosis treatment

• Emerging AL Amyloidosis therapies in the different phases of clinical trials are- LambdaMab, ZN d5, STI-6129, Isatuximab, Bendamustine, Belantamab mafodotin, Ixazomib, CAEL-101, and others are expected to have a significant impact on the AL Amyloidosis market in the coming years.

• In June 2026, Attralus, Inc., a clinical-stage biopharmaceutical company focused on developing innovative therapies for systemic amyloidosis, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to its investigational therapy, zamubafusp alfa (AT-02), for the treatment of light chain (AL) amyloidosis. AL amyloidosis is a rare, progressive disease that can be debilitating and life-threatening. Zamubafusp alfa, Attralus' lead candidate designed to remove amyloid deposits across multiple forms of the disease, has already been assessed in a completed Phase 1 clinical trial. It is now being further evaluated in an ongoing Phase 2 open-label study, with both trials involving patients diagnosed with AL amyloidosis.

• In March 2026, Immix Biopharma, Inc. (NASDAQ: IMMX) announced that it has completed patient enrollment in its Phase II NEXICART-2 trial, which is assessing the CAR-T therapy NXC-201 in patients with relapsed or refractory AL amyloidosis. The company anticipates releasing topline data from the 40-patient study in the third quarter of 2026, with plans to subsequently submit a Biologics License Application (BLA) to the FDA, according to a press release.

• In September 2025, The Phase 1b/2 NEXICART-2 trial (NCT06097832), led by Immix Biopharma and its subsidiary Nexcella, is investigating NXC-201, an experimental autologous BCMA-directed CAR T-cell therapy, for patients with relapsed/refractory (R/R) amyloid light chain (AL) amyloidosis. The study, currently underway in the United States, has surpassed 50% of its targeted enrollment and aims to include a total of 40 participants.

• In July 2025, AstraZeneca’s anselamimab did not demonstrate clinical benefit in patients with light chain (AL) amyloidosis in two Phase III trials. The antibody, designed to deplete light chains, was being evaluated under the Cardiac Amyloid Reaching for Extended Survival (CARES) program in patients with Mayo stage IIIa (NCT04512235) and stage IIIb (NCT04504825) AL amyloidosis. In both studies, the drug failed to reach statistical significance for the primary endpoint, which assessed a composite of time to all-cause mortality (ACM) and incidence of cardiovascular hospitalizations (CVH).

• In June 2025, Birtamimab is an experimental monoclonal antibody developed to target and remove amyloid deposits that lead to organ damage in patients with AL amyloidosis by binding to a specific epitope on kappa and lambda AL proteins. The AFFIRM-AL study (NCT04973137), a double-blind, placebo-controlled, time-to-event clinical trial, evaluated the safety and effectiveness of birtamimab in 207 newly diagnosed, treatment-naïve individuals with Mayo Stage IV AL amyloidosis. Participants were randomized in a 2:1 ratio to receive either birtamimab or placebo intravenously every 28 days, alongside standard-of-care treatment with a bortezomib-based chemotherapy regimen.

• In May 2025, Prothena Corporation plc (NASDAQ: PRTA) announced that its Phase 3 AFFIRM-AL clinical trial evaluating birtamimab for AL amyloidosis did not meet its primary endpoint (HR=0.915, p=0.7680). Consequently, the company has decided to discontinue the development of birtamimab and will also end the open-label extension phase of the AFFIRM-AL study.

• In February 2025, Immix Biopharma, Inc. (Nasdaq: IMMX), a clinical-stage biopharmaceutical company developing cell therapies for AL amyloidosis and immune-mediated conditions, announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its sterically-optimized CAR-T therapy, NXC-201, for the treatment of relapsed/refractory AL amyloidosis. As of June 2024, fewer than half of RMAT requests submitted over the past eight years have received approval. The RMAT designation is reserved for advanced regenerative therapies targeting serious illnesses that show potential—through early clinical data—to treat, modify, reverse, or cure disease and address unmet medical needs.

• In January 2025, Attralus, Inc., a clinical-stage biopharmaceutical company developing novel therapies for systemic amyloidosis, in collaboration with Brigham and Women’s Hospital in Boston, MA, has announced the enrollment of the first patient in the Phase 3 REVEAL study. This clinical trial is evaluating the investigational diagnostic imaging agent 124I-evuzamitide (AT-01) in individuals suspected of having cardiac amyloidosis. The study aims to determine the sensitivity and specificity of 124I-evuzamitide PET/CT imaging for diagnosing the condition. Dr. Sharmila Dorbala, Principal Investigator and Sponsor of the REVEAL study, emphasized the significance of the research, noting that the imaging technique offers a promising noninvasive approach to detecting amyloid deposits in the heart and other organs. Given the serious nature of cardiac amyloidosis, early and accurate diagnosis is critical. With the availability of FDA-approved treatments, a reliable diagnostic scan could play a crucial role in minimizing diagnostic delays and improving patient outcomes.

 

AL Amyloidosis Overview

AL amyloidosis (also known as light chain amyloidosis) is a rare and serious condition caused by the buildup of abnormal proteins called amyloid light chains in organs and tissues. These proteins are produced by malfunctioning plasma cells in the bone marrow and can accumulate in the heart, kidneys, liver, and nerves, leading to organ damage. Symptoms vary depending on the organs affected and may include fatigue, swelling, shortness of breath, and irregular heartbeat. Early diagnosis and treatment—often involving chemotherapy or stem cell transplant—are essential to prevent irreversible organ damage and improve outcomes.

 

Get a Free Sample PDF Report to know more about AL Amyloidosis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/al-amyloidosis-pipeline-insight

 

Emerging AL Amyloidosis Drugs Under Different Phases of Clinical Development Include:

• LambdaMab: HaemaLogiX

• ZN d5: Zentalis Pharmaceuticals

• STI-6129: Sorrento Therapeutics

• Isatuximab: Sanofi

• Bendamustine: Astellas Pharma GmbH

• Belantamab mafodotin: GlaxoSmithKline

• Ixazomib: Takeda Oncology

• CAEL-101: Caelum Biosciences

 

AL Amyloidosis Route of Administration

AL Amyloidosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

 

AL Amyloidosis Molecule Type

AL Amyloidosis Products have been categorized under various Molecule types, such as

• Oligonucleotide

• Peptide

• Small molecule

 

AL Amyloidosis Pipeline Therapeutics Assessment

• AL Amyloidosis Assessment by Product Type

• AL Amyloidosis By Stage and Product Type

• AL Amyloidosis Assessment by Route of Administration

• AL Amyloidosis By Stage and Route of Administration

• AL Amyloidosis Assessment by Molecule Type

• AL Amyloidosis by Stage and Molecule Type

 

DelveInsight's AL Amyloidosis Report covers around 10+ products under different phases of clinical development like

• Late-stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage product (Phase I)

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

• Route of Administration

 

Further AL Amyloidosis product details are provided in the report. Download the AL Amyloidosis pipeline report to learn more about the emerging AL Amyloidosis therapies

 

Some of the key companies in the AL Amyloidosis Therapeutics Market include:

Key companies developing therapies for AL Amyloidosis are - Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharmaceuticals, Takeda, Millennium Pharmaceuticals, Caelum Biosciences, Astellas Pharma GmbH, Oncopeptides, and others.

 

AL Amyloidosis Pipeline Analysis:

The AL Amyloidosis pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of AL Amyloidosis with aggregate therapies developed by each company for the same.

• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for AL Amyloidosis Treatment.

• AL Amyloidosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• AL Amyloidosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the AL Amyloidosis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about AL Amyloidosis drugs and therapies

 

AL Amyloidosis Pipeline Market Drivers

• Increase in the number of patients suffering from AL Amyloidosis, increase in awareness about the disease are some of the important factors that are fueling the AL Amyloidosis Market.

 

AL Amyloidosis Pipeline Market Barriers

• However, high cost of the associated treatment, side effects associated with the treatment and other factors are creating obstacles in the AL Amyloidosis Market growth.

 

Scope of AL Amyloidosis Pipeline Drug Insight

• Coverage: Global

• Key AL Amyloidosis Companies: HaemaLogiX, Zentalis Pharmaceuticals, Sorrento Therapeutics, Sanofi, Astellas Pharma GmbH, GlaxoSmithKline, Takeda Oncology, Caelum Biosciences, and others

• Key AL Amyloidosis Therapies: LambdaMab, ZN d5, STI-6129, Isatuximab, Bendamustine, Belantamab mafodotin, Ixazomib, CAEL-101, and others

• AL Amyloidosis Therapeutic Assessment: AL Amyloidosis current marketed and AL Amyloidosis emerging therapies

• AL Amyloidosis Market Dynamics: AL Amyloidosis market drivers and AL Amyloidosis market barriers

 

Request for Sample PDF Report for AL Amyloidosis Pipeline Assessment and clinical trials

 

Table of Contents

1. AL Amyloidosis Report Introduction

2. AL Amyloidosis Executive Summary

3. AL Amyloidosis Overview

4. AL Amyloidosis- Analytical Perspective In-depth Commercial Assessment

5. AL Amyloidosis Pipeline Therapeutics

6. AL Amyloidosis Late Stage Products (Phase II/III)

7. AL Amyloidosis Mid Stage Products (Phase II)

8. AL Amyloidosis Early Stage Products (Phase I)

9. AL Amyloidosis Preclinical Stage Products

10. AL Amyloidosis Therapeutics Assessment

11. AL Amyloidosis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. AL Amyloidosis Key Companies

14. AL Amyloidosis Key Products

15. AL Amyloidosis Unmet Needs

16 . AL Amyloidosis Market Drivers and Barriers

17. AL Amyloidosis Future Perspectives and Conclusion

18. AL Amyloidosis Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

How Knutzz Lighting and Accessories Is Redefining Ebike Customization with Dual Beam Technology and Stylish Number Plate Kits

"We built Knutzz around two principles: give riders technology that genuinely improves their experience and give them the tools to make their bike look like no one else's. When someone rides a Knutzz-equipped ebike, they are riding something that represents who they are. That is what we mean when we ask, what is your life brand?" - Spokesperson

Knutzz Lighting and Accessories is carving out a unique position in the ebike industry by combining advanced dual beam lighting technology with customizable front number plates. The company champions personal expression on two wheels, encouraging riders to build a bike that reflects their individual identity.

In a market where ebike accessories have traditionally prioritized basic function over personal style, Knutzz Lighting and Accessories is charting a different course. The company has built its identity around the belief that ebike riders deserve both cutting-edge technology and the freedom to customize their ride to reflect their personality. With its dual beam ebike light kits and colorful front number plates, Knutzz is delivering on that promise.

The centerpiece of the Knutzz product lineup is the dual beam lightbar, a system that gives riders the ability to switch between high beam and low beam settings while riding. This capability, standard in automobiles and motorcycles for generations, has until now been virtually nonexistent in the ebike lighting category. Knutzz has developed and refined this technology specifically for the ebike platform, creating a product the company says has no direct competitor in the current market.

The plug and play design of each kit means that installation is accessible to riders of all mechanical skill levels. There is no need for rewiring or modification of the ebike frame or electrical system. The lights draw power from the ebike battery itself, eliminating the hassle of charging separate battery packs or managing additional components. For Macfox ebike owners, Knutzz offers model-specific kits that are tailored for a precise fit. Riders of other ebike brands can choose from the universal kit options, which are designed to be compatible across a broad spectrum of models and frame styles.

What truly sets Knutzz apart from other accessory brands, however, is the emphasis on style and individuality. Every light kit comes with a front number plate that serves as a visual statement piece on the bike. These plates are available in several colors, giving riders the opportunity to match or contrast with their existing bike aesthetics. The result is a finished look that transforms a stock ebike into something distinctly personal.

This philosophy of customization runs deep within the Knutzz brand. The company regularly engages with its growing community of ebike enthusiasts through social media channels, showcasing customer builds and encouraging riders to share their unique setups. The tagline what is your life brand has become a rallying point for Knutzz customers, many of whom view their ebike as more than just a mode of transportation. For these riders, their bike is a canvas for self-expression, and Knutzz provides the tools to make that expression vivid and bold.

The practical benefits of the dual beam system are equally compelling. Riders who commute during early morning or evening hours gain a significant safety advantage with the ability to switch between beam modes depending on their surroundings. High beam illuminates dark paths and rural roads where visibility is critical, while low beam provides appropriate lighting in urban settings where excessive brightness can be a hazard to others. This adaptability makes the Knutzz light kit a versatile companion for riders who encounter varied conditions on a single journey.

As the ebike industry continues its rapid expansion, riders are increasingly looking for ways to differentiate their bikes and enhance their riding experience. Knutzz Lighting and Accessories has identified this intersection of technology and personalization as its core market opportunity. With a product line that addresses both safety and style, the company is positioned to become a go-to brand for ebike enthusiasts who refuse to settle for ordinary. Riders interested in exploring the full product range can visit the Knutzz website for details on available kits and color selections.

CONTACT: https://knutzz.com

https://facebook.com/profile.php?id=61589671867423

https://instagram/knutzzebikes

https://tiktok.com/@knutzzebikes

Media Contact
Company Name: knutzz.com
Contact Person: Kyle Craw
Email:Send Email
Country: United States
Website: https://knutzz.com